MX2015005798A - Terapia de combinacion. - Google Patents
Terapia de combinacion.Info
- Publication number
- MX2015005798A MX2015005798A MX2015005798A MX2015005798A MX2015005798A MX 2015005798 A MX2015005798 A MX 2015005798A MX 2015005798 A MX2015005798 A MX 2015005798A MX 2015005798 A MX2015005798 A MX 2015005798A MX 2015005798 A MX2015005798 A MX 2015005798A
- Authority
- MX
- Mexico
- Prior art keywords
- combination
- inhibiting
- decreasing
- treating
- methods
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000002062 proliferating effect Effects 0.000 abstract 3
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 abstract 2
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000003247 decreasing effect Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- 108091006112 ATPases Proteins 0.000 abstract 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 abstract 1
- 102000044159 Ubiquitin Human genes 0.000 abstract 1
- 108090000848 Ubiquitin Proteins 0.000 abstract 1
- 230000000593 degrading effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723474P | 2012-11-07 | 2012-11-07 | |
| US201361790796P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/068691 WO2014074580A1 (en) | 2012-11-07 | 2013-11-06 | Combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015005798A true MX2015005798A (es) | 2015-09-23 |
Family
ID=49681127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015005798A MX2015005798A (es) | 2012-11-07 | 2013-11-06 | Terapia de combinacion. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20150290204A1 (enExample) |
| EP (1) | EP2916841A1 (enExample) |
| JP (1) | JP2015536986A (enExample) |
| KR (1) | KR20150081344A (enExample) |
| CN (1) | CN105120868A (enExample) |
| AU (2) | AU2013341271A1 (enExample) |
| BR (1) | BR112015010396A2 (enExample) |
| CA (1) | CA2890699A1 (enExample) |
| IN (1) | IN2015DN04175A (enExample) |
| MX (1) | MX2015005798A (enExample) |
| RU (1) | RU2015121424A (enExample) |
| WO (1) | WO2014074580A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014124230A2 (en) | 2013-02-08 | 2014-08-14 | Celgene Avilomics Research, Inc. | Erk inhibitors and uses thereof |
| MX2016008362A (es) * | 2013-12-23 | 2016-09-08 | Novartis Ag | Combinaciones farmaceuticas. |
| ES2741785T3 (es) | 2014-08-13 | 2020-02-12 | Celgene Car Llc | Formas y composiciones de un inhibidor de ERK |
| WO2016098042A1 (en) * | 2014-12-19 | 2016-06-23 | Novartis Ag | Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders |
| US10913744B2 (en) | 2015-02-13 | 2021-02-09 | Dana-Farber Cancer Institute, Inc. | LRRK2 inhibitors and methods of making and using the same |
| US11058977B2 (en) | 2018-07-23 | 2021-07-13 | Caterpillar Inc. | 3D printed staged filtration media packs |
| US10981335B2 (en) | 2019-02-06 | 2021-04-20 | Caterpillar Inc. | Filtration media packs produced using additive manufacturing |
| US11529350B2 (en) | 2019-07-03 | 2022-12-20 | Sumitomo Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |
| GB201915618D0 (en) * | 2019-10-28 | 2019-12-11 | Univ Oslo | ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| WO2022006457A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| WO2022182839A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| JP2025509672A (ja) | 2022-03-17 | 2025-04-11 | インサイト・コーポレイション | Ｊａｋ２ ｖ６１７ｆ阻害剤としての三環式尿素化合物 |
| CN116284001B (zh) * | 2023-01-30 | 2025-06-06 | 中国药科大学 | Dclk1抑制剂、制备方法、药物组合物和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| EA009919B1 (ru) | 2003-02-11 | 2008-04-28 | Вернэлис (Кембридж) Лимитед | Соединения изоксазола |
| JO2783B1 (en) | 2005-09-30 | 2014-03-15 | نوفارتيس ايه جي | Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones |
| BRPI0720264B1 (pt) | 2006-12-08 | 2022-03-03 | Novartis Ag | Compostos e composições como inibidores de proteína cinase |
| CA2763633A1 (en) * | 2009-05-27 | 2010-12-02 | Gary T. Wang | Pyrimidine inhibitors of kinase activity |
| EP2499486A4 (en) * | 2009-11-13 | 2013-11-27 | Infinity Pharmaceuticals Inc | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, EVALUATION, PREVENTION, AND THERAPY OF CANCER |
| US20130137709A1 (en) * | 2010-05-05 | 2013-05-30 | Nathanael S. Gray | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith |
| ME02200B (me) * | 2011-02-02 | 2016-02-20 | Novartis Ag | Postupci za korisćenje alk inhibitora |
| EP2729144A2 (en) * | 2011-07-07 | 2014-05-14 | Synta Pharmaceuticals Corp. | Treating cancer with hsp90 inhibitory compounds |
-
2013
- 2013-11-06 IN IN4175DEN2015 patent/IN2015DN04175A/en unknown
- 2013-11-06 CN CN201380058273.5A patent/CN105120868A/zh active Pending
- 2013-11-06 WO PCT/US2013/068691 patent/WO2014074580A1/en not_active Ceased
- 2013-11-06 RU RU2015121424A patent/RU2015121424A/ru unknown
- 2013-11-06 AU AU2013341271A patent/AU2013341271A1/en not_active Abandoned
- 2013-11-06 BR BR112015010396A patent/BR112015010396A2/pt not_active IP Right Cessation
- 2013-11-06 MX MX2015005798A patent/MX2015005798A/es unknown
- 2013-11-06 EP EP13798786.3A patent/EP2916841A1/en not_active Withdrawn
- 2013-11-06 US US14/440,915 patent/US20150290204A1/en not_active Abandoned
- 2013-11-06 JP JP2015541875A patent/JP2015536986A/ja active Pending
- 2013-11-06 CA CA2890699A patent/CA2890699A1/en not_active Abandoned
- 2013-11-06 KR KR1020157014764A patent/KR20150081344A/ko not_active Withdrawn
-
2016
- 2016-06-16 US US15/184,399 patent/US20160287605A1/en not_active Abandoned
-
2017
- 2017-01-13 AU AU2017200232A patent/AU2017200232A1/en not_active Abandoned
- 2017-02-15 US US15/433,392 patent/US20170157134A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160287605A1 (en) | 2016-10-06 |
| AU2017200232A1 (en) | 2017-02-02 |
| IN2015DN04175A (enExample) | 2015-10-16 |
| BR112015010396A2 (pt) | 2017-07-11 |
| CN105120868A (zh) | 2015-12-02 |
| US20150290204A1 (en) | 2015-10-15 |
| JP2015536986A (ja) | 2015-12-24 |
| EP2916841A1 (en) | 2015-09-16 |
| US20170157134A1 (en) | 2017-06-08 |
| KR20150081344A (ko) | 2015-07-13 |
| RU2015121424A (ru) | 2016-12-27 |
| AU2013341271A1 (en) | 2015-05-14 |
| CA2890699A1 (en) | 2014-05-15 |
| WO2014074580A1 (en) | 2014-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015005798A (es) | Terapia de combinacion. | |
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| JO3776B1 (ar) | التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf | |
| HK1198869A1 (en) | Combination treatments for hepatitis c | |
| WO2015097621A3 (en) | Pharmaceutical combinations | |
| NZ703940A (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| EA201290859A1 (ru) | Лечение люпус-артрита с использованием лаквинимода | |
| MX369385B (es) | Productos para cicatrizar heridas tisulares. | |
| HK1199726A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| MX337614B (es) | Tratamiento de lupus nefritis usando laquinimod. | |
| WO2012159085A3 (en) | Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells | |
| WO2013188847A8 (en) | Compositions and methods for transmucosal absorption | |
| AU2012286851A8 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| MX2010002735A (es) | Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno. | |
| MX352824B (es) | Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación. | |
| MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| UA107550C2 (uk) | Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів | |
| WO2011151722A3 (en) | Methods and compositions for oral pharmaceutical therapy | |
| WO2014164285A3 (en) | Use of levocetirizine and montelukast in the treatment of vasculitis | |
| WO2012100043A3 (en) | Controlled release oral pharmaceutical dosage forms comprising mgbg | |
| MX2012013879A (es) | Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas. | |
| WO2011153458A3 (en) | Compositions and methods for inhibition of or treatment of dengue virus infection | |
| WO2013096335A8 (en) | ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT |